@article{40656e36b6ff4cb5b253e048126e2e36,
title = "Quantitative MRI measures of orbitofrontal cortex in patients with chronic schizophrenia or schizoaffective disorder",
abstract = "The relationship between orbitofrontal cortex (OFC) volumes and functional domains in treatment-resistant patients with schizophrenia or schizoaffective disorder is poorly understood. OFC dysfunction is implicated in several of the behaviors that are abnormal in schizophrenia. However, little is known about the relationship between these behaviors and OFC volumes. Forty-nine patients received magnetic resonance imaging scanning as part of a double-blind treatment study in which psychiatric symptomatology, neuropsychological function, and aggression were measured. OFC volumes were manually traced on anatomical images. Psychiatric symptomatology was measured with the Positive and Negative Syndrome Scale (PANSS). Aggression was measured with the Overt Aggression Scale (OAS) and with the PANSS. Neuropsychological function was assessed using a comprehensive test battery. Larger right OFC volumes were associated with poorer neuropsychological function. Larger left OFC gray matter volumes and larger OFC white matter volumes bilaterally were associated with greater levels of aggression. These findings are discussed in the context of potential iatrogenic effects.",
keywords = "Aggression, Neuropsychological function, Orbitofrontal cortex, Schizophrenia",
author = "Hoptman, {Matthew J.} and Jan Volavka and Weiss, {Elisabeth M.} and P{\'a}l Czobor and Szeszko, {Philip R.} and Guido Gerig and Miranda Chakos and Joseph Blocher and Citrome, {Leslie L.} and Lindenmayer, {Jean Pierre} and Brian Sheitman and Lieberman, {Jeffrey A.} and Bilder, {Robert M.}",
note = "Funding Information: NIMH grant (R10 MH53550) provided the principal support for this project. Additional support was provided by the UNC-Mental Health and Neuroscience Clinical Research Center (MH MH33127) and the Foundation of Hope, Raleigh, North Carolina. We thank Janssen Pharmaceutica Research Foundation, Eli Lilly and Company, Novartis Pharmaceuticals Corporation, and Merck and Co., Inc., for their generous gifts of medications. Eli Lilly and Company contributed supplemental funding. However, overall experimental design, data acquisition, statistical analyses, and interpretation of the results were implemented without any input from any of the pharmaceutical companies. E.M. Weiss was supported by the Austrian Fonds z{\"u}r Foerderung wissenschaftlicher Forschung (FWF: J2227-B05). MJH received additional support from R01 MH064783). JAL is now the Director of New York State Psychiatric Institute, New York, NY and Chairman, Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY.",
year = "2005",
month = nov,
day = "30",
doi = "10.1016/j.pscychresns.2005.07.004",
language = "English",
volume = "140",
pages = "133--145",
journal = "Psychiatry Research - Neuroimaging",
issn = "0925-4927",
publisher = "Elsevier Ireland Ltd",
number = "2",
}